PURPOSE: To analyze macular pigment (MP) amount and distribution in patients with macular telangiectasia Type 2 receiving oral zeaxanthin supplementation in a randomized, open-label, interventional trial. METHODS: Eight macular telangiectasia Type 2 patients were randomized to 10 mg or 20 mg of zeaxanthin per day. At each visit, best-corrected visual acuity, contrast sensitivity, fundus biomicroscopy, color fundus photography, autofluorescence imaging, optical coherence tomography, and serum carotenoid levels were tested. Patients were assessed at baseline and after 6, 12, 18, and 24 months of zeaxanthin supplementation. Concentration of MP was analyzed and calculated from autofluorescence imaging obtained at 488-nm excitation wavelength. Serum carotenoid levels were obtained using high-performance liquid chromatography. RESULTS: The majority of patients had definite increases in the intensity of hypofluorescent ring of MP, but none of them deposited MP centrally at the fovea. Although some patients noted subjective improvements in vision, no objective improvements could be documented, and there were no changes in foveal optical coherence tomographic features. Yellowish, hypofluorescent crystals appeared in one patient's macular region with no change in visual acuity. These inner retinal crystals disappeared several months after discontinuing her 20-mg zeaxanthin supplement. CONCLUSION: Based on the current study, zeaxanthin supplementation does not result in any visual benefit in patients with macular telangiectasia Type 2 and does not reestablish a normal peaked distribution of MP in the fovea. One patient developed a novel, reversible, crystalline maculopathy in response to zeaxanthin supplementation that was reminiscent of canthaxanthin crystalline maculopathy.
PURPOSE: To analyze macular pigment (MP) amount and distribution in patients with macular telangiectasia Type 2 receiving oral zeaxanthin supplementation in a randomized, open-label, interventional trial. METHODS: Eight macular telangiectasia Type 2 patients were randomized to 10 mg or 20 mg of zeaxanthin per day. At each visit, best-corrected visual acuity, contrast sensitivity, fundus biomicroscopy, color fundus photography, autofluorescence imaging, optical coherence tomography, and serum carotenoid levels were tested. Patients were assessed at baseline and after 6, 12, 18, and 24 months of zeaxanthin supplementation. Concentration of MP was analyzed and calculated from autofluorescence imaging obtained at 488-nm excitation wavelength. Serum carotenoid levels were obtained using high-performance liquid chromatography. RESULTS: The majority of patients had definite increases in the intensity of hypofluorescent ring of MP, but none of them deposited MP centrally at the fovea. Although some patients noted subjective improvements in vision, no objective improvements could be documented, and there were no changes in foveal optical coherence tomographic features. Yellowish, hypofluorescent crystals appeared in one patient's macular region with no change in visual acuity. These inner retinal crystals disappeared several months after discontinuing her 20-mg zeaxanthin supplement. CONCLUSION: Based on the current study, zeaxanthin supplementation does not result in any visual benefit in patients with macular telangiectasia Type 2 and does not reestablish a normal peaked distribution of MP in the fovea. One patient developed a novel, reversible, crystalline maculopathy in response to zeaxanthin supplementation that was reminiscent of canthaxanthin crystalline maculopathy.
Authors: Paul S Bernstein; Binxing Li; Preejith P Vachali; Aruna Gorusupudi; Rajalekshmy Shyam; Bradley S Henriksen; John M Nolan Journal: Prog Retin Eye Res Date: 2015-11-02 Impact factor: 21.198
Authors: Peter Charbel Issa; Tos T J M Berendschot; Giovanni Staurenghi; Frank G Holz; Hendrik P N Scholl Journal: Invest Ophthalmol Vis Sci Date: 2008-03 Impact factor: 4.799
Authors: Tyler A Berger; Matthew W Manry; Lucas B Lindsell; James M Osher; Daniel M Miller; Robert E Foster; Christopher D Riemann; Michael R Petersen; Robert A Sisk Journal: Clin Ophthalmol Date: 2021-03-15
Authors: Lydia Sauer; Karl M Andersen; Binxing Li; Rebekah H Gensure; Martin Hammer; Paul S Bernstein Journal: Invest Ophthalmol Vis Sci Date: 2018-06-01 Impact factor: 4.799
Authors: Kiran Chandra Kedarisetti; Raja Narayanan; Michael W Stewart; Nikitha Reddy Gurram; Arshad M Khanani Journal: Clin Ophthalmol Date: 2022-10-10
Authors: Christopher D Conrady; James P Bell; Brian M Besch; Aruna Gorusupudi; Kelliann Farnsworth; Igor Ermakov; Mohsen Sharifzadeh; Maia Ermakova; Werner Gellermann; Paul S Bernstein Journal: Invest Ophthalmol Vis Sci Date: 2017-07-01 Impact factor: 4.799